What is Hyperfine?
Based in Guilford, Connecticut, Hyperfine is redefining the medical device industry through the development of affordable, accessible imaging and monitoring systems. The company specializes in MRI-guided interventions, effectively lowering the barrier to entry for high-quality diagnostic care. By engineering portable, point-of-care MRI technology, Hyperfine addresses the critical need for rapid, bedside imaging in both emergency and routine clinical settings. Their market position is characterized by a focus on technological agility and the integration of advanced data analytics to improve patient outcomes. As a leader in the frontier of medical hardware, Hyperfine bridges the gap between complex diagnostic requirements and the practical constraints of modern healthcare infrastructure.
How much funding has Hyperfine raised?
Hyperfine has raised a total of $5.3M across 2 funding rounds:
Debt
$350K
Series D
$5M
Debt (2020): $350K with participation from PPP
Series D (2021): $5M led by LSS, Huami, Axiom Associates, Colle Capital, Altium Capital, GV, Huami Corporation, and Nextrans
Key Investors in Hyperfine
Huami
A biometric and activity-data-driven company that manufactures smart wearable technology and provides comprehensive analysis of health metrics.
Colle Capital
A global early-stage technology venture fund that emphasizes data-driven management and supports innovation across healthcare and artificial intelligence sectors.
GV
A prominent venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences, enterprise solutions, and frontier technology.
What's next for Hyperfine?
With the successful closure of its latest financing round, Hyperfine is well-positioned to scale its manufacturing capabilities and expand its global footprint. The strategic focus will likely shift toward deepening market penetration in hospital systems and outpatient clinics that require high-frequency, low-latency imaging solutions. Furthermore, the company is expected to leverage this capital to enhance its software-driven diagnostic features, potentially integrating AI-assisted analysis to further streamline the MRI workflow. As Hyperfine continues to mature, the emphasis will remain on maintaining its competitive edge in the medical technology sector while navigating the regulatory and operational complexities of international healthcare markets. The firm's growth trajectory suggests a sustained commitment to innovation, aiming to make advanced imaging a standard component of point-of-care medicine.
See full Hyperfine company page
